Based in Buffalo, New York, OmniSeq offers comprehensive molecular profiling services, including NY State CLEP approved assays and the OmniSeq Comprehensive and Immune Report Card assays. These assays cover all known genomic and immune markers tied to approved therapeutics and clinical trials. OmniSeq is also investing in developing better diagnostics for immuno-oncology therapy selection and collaborates with pharmaceutical companies for research support in immuno-oncology development projects. The company was founded in 2015 and was acquired by Labcorp in July 2022.